Myriad Genetics (MYGN) Cash from Operations (2009 - 2026)

Myriad Genetics (MYGN) has reported Cash from Operations for 18 consecutive years, with 15700000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Operations rose 3.68% year-over-year to 15700000.0; the TTM figure through Mar 2026 stood at 2400000.0 (up 137.5% YoY), while the FY2025 annual figure was 1800000.0, up 120.69% from the prior year.
• Cash from Operations eased to 15700000.0 in Q1 2026 per MYGN's latest filing, from 10600000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 21100000.0 in Q3 2025 and bottomed at 54700000.0 in Q4 2023.
• Historically, Cash from Operations has averaged 14105882.35 across 5 years, with a median of 13600000.0 in 2025.
• Annual changes were most pronounced in 2022 — Cash from Operations sank 1029.55% — and 2025, when it surged 2914.29%.
• Myriad Genetics' Cash from Operations stood at 7300000.0 in 2022, then plunged by 649.32% to 54700000.0 in 2023, then soared by 112.07% to 6600000.0 in 2024, then jumped by 60.61% to 10600000.0 in 2025, then plunged by 248.11% to 15700000.0 in 2026.
• Business Quant data shows MYGN's Cash from Operations at 15700000.0 in Q1 2026, 10600000.0 in Q4 2025, and 21100000.0 in Q3 2025.